Mode
Text Size
Log in / Sign up
N/A N=27 Randomized Quadruple-blind Treatment

Burst Optimized Stimulation Study

Chronic Pain

Enrolled (actual)
27
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Visual Analog Scale (VAS) for Pain — 46.88; 48.60; 46.76 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Abbott Medical Devices
Primary completion
Aug 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analog Scale (VAS) for Pain
46.88; 48.60; 46.76
SECONDARY
EQ-5D
0.59; 0.62; 0.59
SECONDARY
Subject Preference
2; 1; 3; 1; 5; 3
SECONDARY
Subject Satisfaction
3; 5; 7; 12; 8; 8
SECONDARY
Percentage of Participants With Adverse Events
3.7

Summary

This purpose of this study is to evaluate the therapeutic efficacy of burst microdosing stimulation paradigms in patients with chronic pain.

Eligibility Criteria

Inclusion Criteria

  • Subject has been implanted with a commercially available SJM spinal cord stimulator for controlling chronic intractable pain associated with back and/or leg pain;
  • Subject has been exclusively using burst stimulation for at least three months;
  • Subject is 18 years of age or older;
  • Subject's pain-related medication regimen was stable in the 4 weeks prior to the screening evaluation;
  • Subject agrees not to add or increase pain-related medication from enrollment through the study duration;
  • Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;

Exclusion Criteria

  • Subject is currently participating in a clinical investigation study that includes an active treatment arm;
  • Subject is currently receiving, applying or considering seeking workers compensation, or is involved in disability litigation;
  • Subject has a non SJM neuromodulation device
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02896361). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search